The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2017 | The current status of CLL treatment
Ulrich Jäger, MD from the Medical University of Vienna, Vienna, Austria gives an overview on the novel treatments in relapsed/refractory chronic lymphocytic leukemia (CLL) session at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland. Dr Jager explains how current treatments are changing rapidly and discusses 3 new drugs that have been introduced – BCL inhibitor venetoclax, PTK inhibitor ibrutinib and PI3 kinase inhibitor idelalisib. He also touches on minimal residual disease testing, the use of CAR T-cells and the million dollar question – will we be able to cure CLL?
